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P2Y2 receptorAmyloid precursor protein (APP) is expressed in a large variety of neural and non-neural cells. The balance between
non-pathogenic and pathologic forms of APP processing, mediated byα-secretase and β-secretase respectively, re-
mains a crucial step to understand β-amyloid, Aβ42 peptide, formation and aggregation that are at the origin of the
senile plaques in the brain, a characteristic hallmark of Alzheimer's disease (AD). In Neuro-2a, a neuroblastoma cell
line that constitutively expresses APP, activation of the P2X7 receptor leads to reduction ofα-secretase activity, the
opposite effect being obtained by P2Y2 receptor activation.
The in vivo approach wasmade possible by the use of J20mice, a transgenic mousemodel of familial Alzheimer's
disease (FAD) expressing human APP mutant protein. This animal exhibits prominent amyloid plaques by six
months of age. In vivo inhibition of the P2X7 receptor induced a signiﬁcant decrease in the number and size of
hippocampal amyloid plaques. This reduction is mediated by an increase in the proteolytic processing of APP
throughα-secretase activity,which correlateswith an increase in the phosphorylated formof GSK-3, a less active
form of this enzyme. The in vivo ﬁndings corroborate the therapeutic potential of P2X7 antagonists in the
treatment of FAD.
© 2015 Miras-Portugal et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
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Alzheimer's disease (AD) is a progressive and irreversible neurode-
generative disorder characterized by learning and memory impairments,ímica y Biología Molecular IV,
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y/4.0/).being the most common form of senile dementia. The main neuropatho-
logical characteristics of this disease are the accumulation of intracellular
neuroﬁbrillary tangles and extracellular amyloid deposits also known as
senile plaques in brain [1]. The amyloid precursor protein (APP) is a single
helix transmembrane protein expressed in neural and non-neural tissues,
being processed in two different ways by sequential proteases, known as
secretases [2,3]. In brain, sequential proteolysis of APP by β- and γ-
secretases is at the origin of β-amyloid peptide, Aβ42 peptide, which is
the most prominent component of extracellular amyloid deposits. Thetwork of Computational and Structural Biotechnology. This is an open access article under
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Fig. 1. APP and functional P2Y2 receptors are co-expressed in N2a cells. (A) N2a cells were cultured in 0.5% fetal bovine serum-containing medium for 4 days in the presence of 1 mM
DiBucAMP. Afterwards, cells were ﬁxed and immunostainedwith anti-amyloid β cloneWO2 (green) antibody fromMillipore and anti-P2Y2 receptor (red) antibody provided by Alomone
Labs. Nuclei were counterstained with DAPI (blue). Scale bar, 10 μm. Insert shows magniﬁcation of neurite distal region ending in a growth cone-like structure, where high levels of P2Y2
receptor can be observed. (B) Intracellular calcium increments evoked by30 sec stimulationwith 100 μMUDP, UTP, or ATP inN2a cells. Horizontal bars indicate stimulation periods. Traces
represent mean from 150 individual cells. (C) Expression of P2Y2 and P2Y4 receptors was analyzed by RT-PCR in both N2a cells, and adult whole mouse brain mRNA extracts. NTC, non-
template control. For methods see Ref. [30].
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by α- and γ-secretases. Both types of APP processing occur in the central
nervous system (CNS), even in the same cell [4], andmanyquestions arise
concerning what are the physiological signals that keep a necessary bal-
ance between both APP processing ways to avoid an increase of the
amyloidogenic pathway in normal brain [5–7].
Neuroﬁbrillary tangles are the intracellular companion of senile
plaques in AD. These inclusions contain the microtubule-associated
protein, tau, in its hyperphosphorylated forms. This protein, which is
mostly found in neurons, stabilizes microtubules and can be phosphor-
ylated by multiple kinases, among them glycogen synthase kinase 3,
GSK-3. When the balance between phosphorylation and dephosphory-
lation is inaccurate, tau self-assembly occurs. Although most of the ef-
fects reported for tau are at the intracellular level [8], it has been
recently reported that extracellular tau and its peptide fragments be-
have as non-desensitizing agonists onmuscarinicM1 andM3 receptors,
with a sustained cytosolic Ca2+ increase in neural cells [9,10]. On the
other hand, phosphorylated tau or its fragments have to be dephos-
phorylated to be fully active on muscarinic receptors. It is relevant
that one of the ecto-phosphatases involved is the tissue non-speciﬁc al-
kaline phosphatase, TNAP, which is already reported to play a role on
axonal growth [9–14]. These ﬁndings constitute an example about the
complexity of Alzheimer's disease, inwhich a clear hereditary transmis-
sion has only been demonstrated for the FAD early-onset genes, APP
and presenilins PS1 and PS2, whereas the ε4 allele of the APOE gene in-
creases the risk of developing the disease. The meta-analyses and
genome-wide association studies are now contributing to the approach
and understanding of the sporadic, also known as late-onset, AD. These
studies allowed the identiﬁcation of a large number of genes, some re-
lated with innate immunity, cellular signaling or Aβ clearance, which
has contributed to open the ﬁeld to new views and interpretations
[15,16].
β-amyloid peptide production and aggregation is still considered to
be at the origin of Alzheimer's pathology. The possibility of enhancingthe non-amyloidogenic APP processing by different G protein-coupled
neurotransmitter receptors (GPCRs) has been postulated, and modula-
tion of the α-, β- and γ-secretases action on APP by diverse signaling
cascades has been proved [17].
GSK-3, which plays a role in multiple signaling pathways, is among
the enzymes that can inﬂuence Aβ production. It has been reported
that an increase in GSK-3 activity [18] correlates with the phosphoryla-
tion of APP intracellular domain, making it a more suitable substrate for
γ-secretase proteolysis, which enhances Aβ-42 production [19]. More-
over, as already mentioned, GSK-3 is one of the enzymes responsible
for tau phosphorylation [20], thus becoming a link between senile
plaques and neuroﬁbrillary tangle formation.
Among neurotransmitters, nucleotides play a relevant role through
the activation of ionotropic P2X and metabotropic P2Y receptors.
These receptors are widely distributed in CNS, where they regulate
calcium homeostasis, neurotransmitter release and a broad diversity
of intracellular signalling pathways involved in brain physiology and
pathophysiology [21]. The P2X7 receptor, which is abundantly
expressed in CNS, being present in diverse cellular subtypes such asmi-
croglia, astrocytes or neurons, has emerged as a relevant target among
the P2 receptors family [22–25]. Early reports demonstrated the up-
regulation of the P2X7 receptor inmicroglial cells in neuroinﬂammatory
situations, and the beneﬁcial effect of its antagonism [26]. In addition,
P2X7 receptor is receiving special attention in neurodegenerative dis-
eases, such as Huntington's and Parkinson's disease [27,28]. The role
of P2X7 receptor has been more intensively studied in Alzheimer's dis-
ease, where the effects of the signalling cascades coupled to P2X7 acti-
vation on APP processing have been reported [29,30]. Other P2
receptors, as it is the case for P2Y2 receptor, have also been involved
in APP processing regulation, mainly through activation of the non-
amyloidogenic pathway [31–33]. In this review the role of P2X7 and
P2Y2 receptors on the APP processing will be discussed, together with
the relevance of experimental models and the possibility of use of
those receptors as valuable therapeutic targets.
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P2X7 receptors activation
The Neuro-2a cell line, N2a, has been largely employed as a neural
model to study signalling pathways, secretory events and neuronal dif-
ferentiation, thus being a well characterized system [34,35]. These cells
have the advantage of constitutively expressing APP, together with
functional P2Y2 and P2X7 receptors. P2Y2 receptors are abundant in
N2a cells, exhibiting a broad distribution, which can be observed even
when neural-like differentiation is induced, as shown in Fig. 1A. The
same ﬁgure shows the APP distribution along the axon until reaching
the axonal growth cone, where a great abundance of the P2Y2 receptor
can be observed. This distribution agrees with a recent ﬂuorescence-
based procedure allowing the study of the axonal transport of APP in
cultured hippocampal neurons [36]. The absence of P2Y4 receptor in
N2a cells (Fig. 1C), which exhibits a similar agonistic proﬁle as the
P2Y2 receptor (Fig. 1B), clearly substantiates a role for P2Y2 receptor ac-
tivation in APP processing.
P2X7 receptor immunolabelling shows a distribution similar to that
observed for APP, being present not only in the neuronal cell body, but
also in the axon-like extension [37,38] (Fig. 2A). The presence of a func-
tional P2X7 receptor has been demonstrated by calcium imaging ﬂuo-
rescence techniques, challenging neural cells with the selective P2X7
receptor agonist benzoyl ATP (BzATP) in the presence or absence of
Mg2+ ions (Fig. 2B), and also by electrophysiological techniques inA
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Fig. 2. APP and functional P2X7 receptors are co-expressed in N2a cells. (A) N2a cells were cu
DiBucAMP. Afterwards, cells were ﬁxed and immunostained with anti-amyloid β clone WO2
Alomone Labs. Merge image with DAPI-labelled nucleus (blue) is shown (lower panel). Scale b
potentiated in the absence of extracellular Mg2+ ions. Horizontal bar indicates stimulation p
whole-cell current responses evoked by 100 μM BzATP in N2a cells. Top panel: current resp
BzATP was applied at 5 min intervals and A438079 was superfused 2 min before and during th
applications of BzATP in the absence or presence of A438079 (four cells). Drugswere administer
Vh =−70 mV. *p b 0.05, unpaired Student's t test. For methods see Ref. [34].which the current elicited by stimulation with BzATP and the inhibition
exerted by the speciﬁc reversible antagonist A438079 were measured
(Fig. 2C).
APP processing in N2a cells can be followed by detection of the
speciﬁc proteolytic fragments present in the plasma membranes. The
presence of the carboxy-terminal C83 fragment, α-CTF, indicates that
membrane protein APP has been processed by α-secretase, which re-
sults in the simultaneous release of the extracellular protein moiety,
APPsα. The C83 fragment is further hydrolysed by γ-secretase that
cleaves the carboxy-terminal fragment in themiddle of APP transmem-
brane helix, which results in the release of the extracellular peptide, P3,
and an intracellular C-terminal fragment, AICD. The AICD fragment is
identical in both the amyloidogenic and non-amyloidogenic APP pro-
cessing, and a role on the control of gene expression has beenpostulated
for this fragment [39].
P2Y2 receptor agonists are able to signiﬁcantly increase the α-
secretase-mediated APP processing in N2a cells, this stimulatory effect
being consequently blocked by the broad spectrum P2 antagonist,
suramin, as shown in Fig. 3A. These results agree with those obtained
by other groups (as Gary Weisman's group), supporting the role of
P2Y2 receptor in neuroprotection, an effect that is mediated at least in
part via the activation of the APP non-amyloidogenic pathway through
α-secretase processing [31–33,40].
The activation of P2X7 receptor in N2a cells decreases the levels of
C83 fragment, which is the indicator of the α-secretase non-B
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Fig. 3. Purinergic receptors regulate α-secretase and GSK-3 activities in N2a cells. (A) Protein levels of CTF C83 detected in N2a cells treated with the P2Y2R agonist Up4U (1 μM), both
suramin (100 μM) and Up4U (1 μM), BzATP (100 μM), A438079 (1 μM), BBG (1 μM), or SB216763 (1 μM). Histogram represents themean± SEM of CTF C83/α-tubulin ratios normalized
to control untreated cells (n= 4 independent experiments in duplicate). (B)Western blot detection of p-GSK-3β (pSer9) and total GSK-3 in N2a cells treated with BBG (1 μM), A438079
(1 μM) or BzATP (100 μM). Histogram represents the mean ± SEM of p-GSK-3β/total GSK-3β ratios (n = 3 independent experiments in duplicate). In all cases, α-tubulin was used as
loading control, and ratios were normalized to control untreated cells (100%). *p b 0.05, **p b 0.01, ***p b 0.005 compared to control using ANOVA with Dunnet´s post-test analysis. For
methods see Ref. [49].
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fect can be overturned by using P2X7 receptor antagonists; both the re-
versible and more speciﬁc A438079 and the wider spectrum less
speciﬁc Brilliant blue G (BBG) were able to increase the C83 fragment
product of α-secretase (Fig. 3A). These results contrast with those ob-
tained by other authors, but it is relevant to emphasize that APP pro-
cessing depends on the abundance of this protein at the speciﬁc
cellular model and in addition, when it is overexpressed, the equilibri-
um between the different proteolytic pathways could be unbalanced,
making it more difﬁcult to understand the process [29,41].
The effect of P2X7 receptor-activated signaling cascades on GSK-3
activity has been already reported by several authors. Activation of
P2X7 receptor in granule cells from cerebellum results in GSK-3 phos-
phorylation through the PI3K/AKT cascade, which in turn promotes
neuroprotection [23,42]. However, P2X7 receptor activation induces a
reduction of GSK-3 phosphorylation and stops axonal elongation in em-
bryonic hippocampal neurons during differentiation, both effects being
reverted by P2X7 receptor antagonists or by the reduction of the extra-
cellular levels of ATP ligand by the use of alkaline phosphatase [38]. N2a
cells, behave in a similarway to cultured hippocampal neurons, as stim-
ulation with P2X7 receptor agonist results in a decrease of GSK-3 phos-
phorylation in serine 9/21 as shown in Fig. 3B, which correlates with areduction in the α-secretase-generated C83 APP fragment (Fig. 3A).
Consequently, the P2X7 receptor antagonists, A438079 and BBG, signif-
icantly increased GSK-3 phosphorylation and production of C83 frag-
ment (Fig. 3A and B). A similar effect was obtained with the GSK-3
inhibitor SB216763 (Fig. 3A), thus corroborating the pharmacological
relevance of the inhibitors of this enzyme in AD.
3. P2X7 receptor and its role in animal models of Familial
Alzheimer's Disease
There are many models of genetically modiﬁed mice that develop
cerebral amyloid deposits. The transgenic mice known as J20 hAPP
have been chosen because they develop the characteristic amyloid pep-
tide deposits by 6–8 months of age. These transgenic mice, labelled as
B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2J strain, express a mutant form of
the human amyloid protein precursor bearing both the Swedish
(K670N/M671L) and the Indiana (V717F) mutations (APPSwInd), [43].
All procedureswere carried out in accordancewith European and Span-
ish regulations (86/609/CEE; RD1201/2005) when working with these
animals in our laboratory.
Themain questionwas to understand the balance between bothAPP
proteolytic pathways in in vivo situations andwhether it was possible to
180 M.T. Miras-Portugal et al. / Computational and Structural Biotechnology Journal 13 (2015) 176–181change the dynamics of amyloid deposits by impacting P2Y2 and P2X7
receptors.
Concerning P2Y2 receptor, there are not selective agonists or antag-
onists with good pharmacokinetics parameters for in vivo administra-
tion to date. However, its relevance has been conﬁrmed in the
TgCRND8 mouse model of Alzheimer's disease, where loss of P2Y2 nu-
cleotide receptors enhances the β-amyloid (Aβ) deposit and also the
soluble Aβ1–42 levels in the cerebral cortex and hippocampus [31].
The availability of P2X7 receptor ligands for in vivo studies is slightly
better, as the antagonist BBG is able to inﬁltrate the brain parenchyma.
The efﬁcacy of this antagonist in mice has been already reported in the
beneﬁcial effects on Huntington's disease symptomatology and the sei-
zure suppression and neuroprotection in status epilepticus [27,44]. Re-
cently, BBG has proved to improve cognition in an animal model of
Alzheimer's disease [45]. In addition to BBG, there are many other
P2X7 receptor antagonists able to reach the brain, as it is the case of
A438079 [46].
The hippocampi of the J20 mice showed abundant amyloid plaques
at the age of 6–8 months. These deposits were clearly identiﬁed with
anti-Aβ antibodies and the Thioﬂavin-T dye that is able to intercalate
between the β-sheet structures of amyloid deposits. To study the role
of P2X7 receptor on β-amyloid deposits in vivo, J20 mice were treated
before the appearance of the ﬁrst hippocampal plaques, at the age of
4 months, with BBG (intraperitoneally injected every 48 hours at
45.5 mg/Kg), or vehicle solution, PBS, for 4 months. BBG concentration
attained in brain was around 200 nM at the dose used. It is relevant to
emphasize that the concentration reached in vivo is in the range of the
IC50 of BBG to antagonize P2X7 receptor (10–200 nM) [47].
After BBG treatment the number and size of amyloid plaques at the
hippocampal structures of J20 mice were signiﬁcantly reduced com-
pared to their littermates treated with vehicle, as shown in Fig. 4A and
B. In addition, the treatment with BBG did not signiﬁcantly modify ei-
ther the P2X7 receptor or murine APP and human APP mRNA expres-
sion. The levels of these proteins and their distribution patterns in theJ20 BBG J20 PB
J20 BBG J20 PB
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Fig. 4. Brilliant Blue-G (BBG) treatment reduces the number of amyloid plaques andmicroglia in
8 months-old J20 mice injected intraperitoneal with vehicle or BBG. Scale bar, 500 μm. (B) Histo
J20 mice treated with vehicle or BBG, being 16 slices per mouse (n = 7mice per condition). ***
pocampal slices from6 to 8months-old J20mice treatedwith vehicle or BBG. Scale bar, 500 μm. (
BBG. Histograms represent the mean ± SEM of microglial cells per hippocampal area of 0.1 mhippocampus were also not modiﬁed by the treatment with BBG, as
demonstrated bywestern blot and immunohistochemical studies. How-
ever, a dramatic changewas observed concerning the pattern of the C83
and C99 peptides, which correspond to the carboxyterminal fragments
generated byAPP cleavage byα-secretase andβ-secretase, respectively.
C99 fragment was under the limits of detection in wild type mouse
brain, but was very abundant in the brain of J20 mice, which exhibit a
much lower concentration of the α-secretase generated C83 fragment.
However, BBG reversed the situation and a signiﬁcant increase in the
C83 fragment was achieved in the brain of BBG-treated J20 mice [48].
This situation mimics the APP processing pattern observed in N2a cells
treated with P2X7 receptor inhibitors. On the other hand, an increase
in the phosphorylated form of GSK-3 was observed in the hippocampus
of BBG-treated J20 mice, when compared with vehicle-treated animals.
Thus, BBGwas able to reduce hippocampal GSK-3 activity in FAD animal
models in the same way as in N2a cells.
J20 animals at the end of their lives, about 20 months-old, exhibit
a profusion of hippocampal senile plaques that were surrounded by
microglial cells. However, at the ﬁrst stages of the FAD neurodegen-
erative disease a signiﬁcant presence of microglial positive cells can-
not be observed when considering the total hippocampal structures
(Fig. 4C and D). Only some few cells surrounding the senile plaques
expressed microglial markers, together with P2X7 receptor and
hypophosphorylated GSK-3. This fact is relevant because to date,
most of the effects of P2X7, and also P2Y2, receptors have been ex-
plained by microglia activation around the senile plaques due to
the amyloid Aβ-42 peptide or the release of extracellular nucleo-
tides and cytokines, thus helping in the extracellular clearance of
the amyloid deposits [26,29,31,49].
4. Summary and Outlook
In spite of the complexity of Alzheimer's disease physiopathology, it
is however relevant to tackle one of the main characteristics of theS
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the J20mouse hippocampus. (A) Immunostaining ofWO2 in hippocampal slices from6 to
gram represents themean± SEM of Aβ-amyloid plaques per slice in the hippocampus of
p b 0.005, unpaired Student's t test. (C) Immunostaining of microglial marker Iba-1 in hip-
D)Quantiﬁcation ofmicroglial cells in thehippocampus of J20mice treatedwith vehicle or
m2 being 16 slices per mouse (n = 7 mice per treatment). For methods see Ref. [49].
181M.T. Miras-Portugal et al. / Computational and Structural Biotechnology Journal 13 (2015) 176–181disease, the formation of amyloid plaques, using an in vivomousemodel
of FAD. In this model, it was demonstrated for the ﬁrst time that the
in vivo inhibition of P2X7 receptors signiﬁcantly reduces the amyloid
plaques formation in brain hippocampal structures. The molecular
mechanisms underneath this relevant effect, reported here, were the
phosphorylation and consequent reduction of GSK-3 activity, which
correlates with an increase in α-secretase activity. Apparently, the
prolonged BBG treatment is efﬁcient and non-toxic, thus providing a
suitable therapeutic approach to prevent amyloid deposition on FAD.
However, remarkable differences exist when studying the effects of
P2X7 receptor agonists and antagonists in various neural cell models.
N2a cells and primary cultures of embryonic hippocampal neurons, be-
have as the adult hippocampus neurons regarding APP processing. By
contrast, P2X7 receptor activation in cultured cerebellar granule neurons
results in GSK-3 inhibition and neuroprotection. Consequently, although
signiﬁcant progress has been made over the past decade understanding
AD and β-amyloid deposit, it is relevant to emphasize that the brain is a
complex entity where many different structures coexist.
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